X9d79253b.8c45.4bde.a42d.c399fb107400
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
- age_years
- 64
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.560
- MYOGENESIS+0.430
- TGF_BETA_SIGNALING+0.430
- HEDGEHOG_SIGNALING+0.390
- HYPOXIA+0.380
- UV_RESPONSE_DN+0.340
- WNT_BETA_CATENIN_SIGNALING+0.320
- ANGIOGENESIS+0.310
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.310
- COAGULATION+0.290
Top 10 suppressed
- E2F_TARGETS-0.590
- G2M_CHECKPOINT-0.590
- INTERFERON_ALPHA_RESPONSE-0.580
- INTERFERON_GAMMA_RESPONSE-0.480
- MYC_TARGETS_V2-0.480
- ALLOGRAFT_REJECTION-0.420
- MYC_TARGETS_V1-0.400
- IL6_JAK_STAT3_SIGNALING-0.340
- INFLAMMATORY_RESPONSE-0.310
- OXIDATIVE_PHOSPHORYLATION-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 20030071.Her2HRpos | — | A | 0.856 |
| 2 | SRR26320067 | — | — | 0.831 |
| 3 | TCGA-56-8622-01A-11R-2403-07 | — | cohortSQ1 | 0.817 |
| 4 | TCGA-HD-7831-01A-11R-2132-07 | — | — | 0.810 |
| 5 | SRR8613703 | — | D | 0.809 |
| 6 | TCGA-E9-A1NH-01A-11R-A14D-07 | — | A | 0.807 |
| 7 | 20020009.LumA | — | A | 0.807 |
| 8 | SRR6013580 | — | cohortA2 | 0.807 |
| 9 | SRR8613790 | — | A | 0.805 |
| 10 | SRR1313111 | — | A | 0.803 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.560 | Inavolisib | — uncovered |
| MYOGENESIS | 0.430 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.430 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.390 | Inavolisib | — uncovered |
| HYPOXIA | 0.380 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.340 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.320 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.310 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.310 | Inavolisib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.280 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.230 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.180 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.170 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.160 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.150 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.080 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.080 | Idelalisib | — uncovered |
| APOPTOSIS | 0.050 | Idelalisib | — uncovered |